Last updated: February 20, 2026
Which companies manufacture and supply cefixime?
Cefixime is a third-generation cephalosporin antibiotic used to treat bacterial infections. It is produced by multiple pharmaceutical companies worldwide, both originators and generic manufacturers.
Major Suppliers and Manufacturers
| Company |
Country |
Product Status |
Market Presence |
| GSK (GlaxoSmithKline) |
United Kingdom |
Originator (Suprax) |
Widely available worldwide, particularly in developed markets |
| Hikma Pharmaceuticals |
Jordan |
Generic |
Significant presence in Middle East and Africa |
| Aurobindo Pharma |
India |
Generic |
Large exporter, active in North America and Europe |
| Teva Pharmaceutical Industries |
Israel |
Generic |
Major global distributor, including North America, Europe |
| Sandoz (Novartis) |
Switzerland |
Generic |
Extensive global footprint |
| Cipla |
India |
Generic |
Strong presence in Asia, Africa, and emerging markets |
| Lupin Limited |
India |
Generic |
North America, Africa, Southeast Asia |
| Sun Pharma |
India |
Generic |
International markets, emerging economies |
| Mylan (Now part of Viatris) |
USA |
Generic |
Global reach, especially in North America |
Supply Chain Considerations
- Originators: GSK markets Cefixime under the brand name Suprax. They generally maintain tighter control over manufacturing and distribution.
- Generic Manufacturers: Companies such as Aurobindo, Teva, Sandoz, Cipla, Lupin, and Sun Pharma produce cefixime in various formulations (capsules, tablets, suspensions). These companies often operate multiple manufacturing sites across continents.
- Regulatory Compliance: Top suppliers typically hold approvals from bodies like the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and equivalent organizations within their regions.
- Market Trends: The generic cefixime market has grown due to increased demand and patent expirations of originator drugs, expanding the number of suppliers.
Geographic Market Breakdown
- North America: Leading demand primarily supplied by Teva, Sandoz, and Mylan.
- Europe: Supplies from Sandoz, Teva, and local manufacturers.
- Asia: Major production hubs for generic cefixime, with Indian companies dominating the market.
- Africa & Middle East: Hikma Pharmaceuticals strongly positioned as a key supplier.
Supply Dynamics
- Manufacturers typically supply cefixime as:
- 100 mg and 200 mg capsules
- Oral suspension (usually 100 mg/5 mL)
- Pricing and availability depend on regulatory approvals, manufacturing capacity, and regional patent statuses.
Key Considerations for Buyers
- Verify supplier regulatory approvals in specific markets
- Assess manufacturing capacity and lead times
- Confirm formulation types and strengths
- Evaluate compliance with Good Manufacturing Practice (GMP)
Conclusion
Multiple companies across regions produce cefixime, with a mix of originator and generic suppliers. Indian companies such as Aurobindo, Cipla, and Sun Pharma dominate in volume. European and Israeli firms like Sandoz and Teva provide substantial global supply. Market dynamics hinge on regulatory approvals, manufacturing capacity, and regional demand.
Key Takeaways
- No single supplier dominates the global cefixime market.
- Indian generic manufacturers are key suppliers globally.
- Originator drugs like Suprax are primarily marketed by GSK.
- Supply chain reliability depends on regulatory approvals and manufacturing scale.
- Market expansion correlates with generic drug approvals and regional demand.
FAQs
Q1: Which company is the original manufacturer of cefixime?
A: GlaxoSmithKline (GSK) marketed the original cefixime under the brand name Suprax.
Q2: Are Indian companies the primary suppliers of generic cefixime?
A: Yes, companies like Aurobindo Pharma, Cipla, Lupin, and Sun Pharma are leading generic cefixime suppliers globally.
Q3: What formulations of cefixime are widely available?
A: Cefixime is commonly available as capsules (100 mg, 200 mg) and oral suspension (100 mg/5 mL).
Q4: How does regional regulation impact cefixime supply?
A: Regulatory approvals from agencies such as the FDA or EMA influence whether suppliers can market cefixime in specific markets, affecting supply and pricing.
Q5: What factors influence cefixime market stability?
A: Market stability hinges on regulatory compliance, production capacity, patent expirations, and regional demand fluctuations.
References
- U.S. Food and Drug Administration. (2023). Approval data. https://www.fda.gov
- European Medicines Agency. (2023). MA overview of cefixime. https://www.ema.europa.eu
- IQVIA. (2022). Global pharmaceutical market analysis.
- GlobalData. (2023). Antibiotics market report.
- World Health Organization. (2021). Model list of essential medicines.
